New hope for lung cancer patients with brain tumors: drug duo targets resistant disease
NCT ID NCT07197008
First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 24 times
Summary
This study tests a combination of two drugs (Sac-TMT and bevacizumab) in 50 adults with a specific type of lung cancer (EGFR-mutant nonsquamous NSCLC) that has spread to the brain and stopped responding to standard targeted therapy. The goal is to see if the combo can shrink brain tumors and delay further growth. Participants will receive the drugs intravenously and be monitored for side effects and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.